Evidence map›Paper›PMID 39719412›Full record

Trial reportJournal of the American Heart Association2025

Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON-HF.

Henri Lu, Riccardo M Inciardi, Martin Abanda, Amil M Shah, Maja Cikes, Brian L Claggett, Narayana Prasad, Carolyn S P Lam, Margaret Redfield, John J V McMurray and 4 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Henri LuDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-9074-6505
Riccardo M InciardiDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia University of Brescia Italy.ORCID 0000-0003-4846-8529
Martin AbandaDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-0789-9691
Amil M ShahDivision of Cardiovascular Medicine University of Texas Southwestern Medical Center Dallas TX USA.ORCID 0000-0003-1056-4451
Maja CikesDepartment of Cardiovascular Diseases University of Zagreb School of Medicine, University Hospital Centre Zagreb Zagreb Croatia.ORCID 0000-0002-4772-5549
Brian L ClaggettDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-4215-9218
Narayana PrasadDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-6280-2741
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore Singapore.ORCID 0000-0003-1903-0018
Margaret RedfieldDepartment of Cardiovascular Disease, Division of Circulatory Failure Mayo Clinic Rochester MN USA.ORCID 0000-0002-0946-7518
John J V McMurrayBritish Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health University of Glasgow United Kingdom.ORCID 0000-0002-6317-3975
Marc A PfefferDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0003-3876-7568
Scott D SolomonDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0003-3698-9597
Sheila M HegdeDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0001-8157-8899
Hicham SkaliDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-5629-4138

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to characterize right ventricular dysfunction (RVD) in heart failure (HF) with preserved ejection fraction and understand the cumulative prognostic value of abnormal RV echocardiographic parameters in HF with preserved ejection fraction. METHODS AND

resultsData from 809 patients in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction) echocardiographic substudy (55% women, mean age 74±8 years) were analyzed. Correlates of RVD (defined as tricuspid annular plane systolic excursion <1.7 cm, fractional area change <35% or absolute RV free wall longitudinal strain <20%) were identified using multivariable logistic regression models. We further assessed the prognostic value of the number of abnormal RV parameters (0, 1, ≥2) on total HF hospitalizations (HFH) and cardiovascular death, total HFH, first HFH or cardiovascular death, all-cause death, and cardiovascular death. RVD was identified in 461 (57%) patients. Correlates of RVD included older age, higher heart rate, atrial fibrillation/flutter, greater left ventricle wall thickness, higher N-terminal pro-B-type natriuretic peptide levels, lower systolic blood pressure, and lower left ventricle absolute global longitudinal strain. These results were consistent across sexes, except atrial fibrillation/flutter and LV wall thickness, which were associated with a higher risk of RVD in men but not in women. Participants with ≥2 abnormal RV parameters had a significantly higher adjusted risk of total HFH and cardiovascular death (rate ratio, 2.13 [95% CI, 1.13-4.01]), first HFH or cardiovascular death, all-cause death, and cardiovascular death. Conversely, an isolated abnormal RV parameter was not associated with a worse outcome.

conclusionsRV measures may underestimate the burden of RVD in HF with preserved ejection fraction when considered in isolation. Clinicians should consider multiple dimensions to comprehensively assess RV function in patients with HF with preserved ejection fraction.

Indexed as

Heart FailureStroke VolumeVentricular Dysfunction, RightVentricular Function, RightAgedAged, 80 and overAngiotensin Receptor AntagonistsEchocardiographyFemaleHospitalizationHumansMaleMiddle AgedPredictive Value of TestsPrognosisProspective StudiesAngiotensin Receptor Antagonistsechocardiographyheart failure with preserved ejection fractionright ventricular dysfunctionsacubitril/valsartan

Identifiers

PMID39719412
PMCPMC12054471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.